Express News | Ocean Biomedical- Ownership in Virion to Equal 22% of Virion's Issued & Outstanding Membership Interests, in Exchange for $9 Mln
Express News | Ocean Biomedical- Ratified Fully Countersigned Copy of Revised Agreement With Virion Therapeutics Received on Sept 26
Molecure (WSE: MOC) and Nasdaq-listed Biotechnology Company Ocean Biomedical (NASDAQ: OCEA) Sign an Exclusive Licensing Agreement for the Development and Commercialization of Selective YKL-40 Inhibitors.
Ocean Biomedical Announces Publication Of New Data Deepening Understanding Of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 And Its Ability To Inhibit Anti-Tumor And Related Tissue Remodeling Responses
Ocean Biomedical's Scientific Co-founder Jonathan Kurtis Issued US Patent For PfGARP Malaria Antibody
Ocean Biomedical Faces Nasdaq Compliance Challenges